The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Humanized versus murinized CD19/CD22 CAR-T cell therapy for R/R B-cell lymphoma
In this video, Peihua Lu, MD, Beijing Lu Daopei Institute of Hematology, and Hebei Yanda Lu Daopei Hospital, Langfang, China, discusses the results of a study comparing the safety and efficacy of humanized versus murinized dual-targeting CD19/CD22 CAR-T cells for relapsed/refractory (R/R) lymphoma. While both products were well-tolerated, the overall response rate (ORR) was higher in patients receiving humanized CAR-T cells, and Dr Lu mentions the need for a longer follow-up of this study. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
